Review



vip receptor antagonist viphyb  (GL Biochem)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    GL Biochem vip receptor antagonist viphyb
    <t>VIP</t> regulates AM and IFN-α/β responses post-RSV infection. (a) AM percentages at 12 h postinfection in lung tissues of KCF mice with or without <t>VIPhyb</t> treatment. (b) IFN-α/β secretion at 12 h postinfection as measured in BALF samples from KCF mice with or without VIPhyb treatment. (c) AM percentages at 12 h postinfection in lung tissues of intact mice with or without VIP treatment. (d) IFN-α/β secretion at 12 h postinfection as measured in BALF samples from intact mice with or without VIP treatment. *, P < 0.05, and **, P < 0.01, compared with RSV or KCF-RSV group; ## , P < 0.01, and ### , P < 0.001, compared with VIP-RSV group. Data are representative of 2 independent experiments. Error bars show SEM.
    Vip Receptor Antagonist Viphyb, supplied by GL Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vip+receptor+antagonist+viphyb/vip+receptor+antagonist+viphyb/pmc09769737-148-4-11
    Average 90 stars, based on 1 article reviews
    vip receptor antagonist viphyb - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "C-Fiber Degeneration Enhances Alveolar Macrophage-Mediated IFN-α/β Response to Respiratory Syncytial Virus"

    Article Title: C-Fiber Degeneration Enhances Alveolar Macrophage-Mediated IFN-α/β Response to Respiratory Syncytial Virus

    Journal: Microbiology Spectrum

    doi: 10.1128/spectrum.02410-22

    VIP regulates AM and IFN-α/β responses post-RSV infection. (a) AM percentages at 12 h postinfection in lung tissues of KCF mice with or without VIPhyb treatment. (b) IFN-α/β secretion at 12 h postinfection as measured in BALF samples from KCF mice with or without VIPhyb treatment. (c) AM percentages at 12 h postinfection in lung tissues of intact mice with or without VIP treatment. (d) IFN-α/β secretion at 12 h postinfection as measured in BALF samples from intact mice with or without VIP treatment. *, P < 0.05, and **, P < 0.01, compared with RSV or KCF-RSV group; ## , P < 0.01, and ### , P < 0.001, compared with VIP-RSV group. Data are representative of 2 independent experiments. Error bars show SEM.
    Figure Legend Snippet: VIP regulates AM and IFN-α/β responses post-RSV infection. (a) AM percentages at 12 h postinfection in lung tissues of KCF mice with or without VIPhyb treatment. (b) IFN-α/β secretion at 12 h postinfection as measured in BALF samples from KCF mice with or without VIPhyb treatment. (c) AM percentages at 12 h postinfection in lung tissues of intact mice with or without VIP treatment. (d) IFN-α/β secretion at 12 h postinfection as measured in BALF samples from intact mice with or without VIP treatment. *, P < 0.05, and **, P < 0.01, compared with RSV or KCF-RSV group; ## , P < 0.01, and ### , P < 0.001, compared with VIP-RSV group. Data are representative of 2 independent experiments. Error bars show SEM.

    Techniques Used: Infection

    VIP protects against RSV infection. (a) RSV titers in lung tissues of KCF mice with or without VIPhyb treatment. (b) Representative lung histopathological images and scores of KCF mice with or without VIPhyb treatment. Scale bar = 50 μm. (c) RSV titers in lung tissues of intact mice with or without VIP treatment. (d) Representative lung histopathological images and scores of intact mice with or without VIP treatment. *, P < 0.05, and **, P < 0.01, compared with RSV or KCF-RSV group. Data are representative of 2 independent experiments. Error bars show SEM.
    Figure Legend Snippet: VIP protects against RSV infection. (a) RSV titers in lung tissues of KCF mice with or without VIPhyb treatment. (b) Representative lung histopathological images and scores of KCF mice with or without VIPhyb treatment. Scale bar = 50 μm. (c) RSV titers in lung tissues of intact mice with or without VIP treatment. (d) Representative lung histopathological images and scores of intact mice with or without VIP treatment. *, P < 0.05, and **, P < 0.01, compared with RSV or KCF-RSV group. Data are representative of 2 independent experiments. Error bars show SEM.

    Techniques Used: Infection

    Sequences of VIPhyb and VIP
    Figure Legend Snippet: Sequences of VIPhyb and VIP

    Techniques Used: Sequencing

    Related Articles

    Synthesized:

    Article Title: C-Fiber Degeneration Enhances Alveolar Macrophage-Mediated IFN-α/β Response to Respiratory Syncytial Virus
    Article Snippet: .. Both VIP and the VIP receptor antagonist VIPhyb were synthesized by GL Biochem Ltd. (Shanghai, China), with purities of >98%. ..



    Similar Products

    vip receptor antagonist viphyb  (GL Biochem)
    90
    GL Biochem vip receptor antagonist viphyb
    <t>VIP</t> regulates AM and IFN-α/β responses post-RSV infection. (a) AM percentages at 12 h postinfection in lung tissues of KCF mice with or without <t>VIPhyb</t> treatment. (b) IFN-α/β secretion at 12 h postinfection as measured in BALF samples from KCF mice with or without VIPhyb treatment. (c) AM percentages at 12 h postinfection in lung tissues of intact mice with or without VIP treatment. (d) IFN-α/β secretion at 12 h postinfection as measured in BALF samples from intact mice with or without VIP treatment. *, P < 0.05, and **, P < 0.01, compared with RSV or KCF-RSV group; ## , P < 0.01, and ### , P < 0.001, compared with VIP-RSV group. Data are representative of 2 independent experiments. Error bars show SEM.
    Vip Receptor Antagonist Viphyb, supplied by GL Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/vip+receptor+antagonist+viphyb/vip+receptor+antagonist+viphyb/pmc09769737-148-4-11
    Average 90 stars, based on 1 article reviews
    vip receptor antagonist viphyb - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    VIP regulates AM and IFN-α/β responses post-RSV infection. (a) AM percentages at 12 h postinfection in lung tissues of KCF mice with or without VIPhyb treatment. (b) IFN-α/β secretion at 12 h postinfection as measured in BALF samples from KCF mice with or without VIPhyb treatment. (c) AM percentages at 12 h postinfection in lung tissues of intact mice with or without VIP treatment. (d) IFN-α/β secretion at 12 h postinfection as measured in BALF samples from intact mice with or without VIP treatment. *, P < 0.05, and **, P < 0.01, compared with RSV or KCF-RSV group; ## , P < 0.01, and ### , P < 0.001, compared with VIP-RSV group. Data are representative of 2 independent experiments. Error bars show SEM.

    Journal: Microbiology Spectrum

    Article Title: C-Fiber Degeneration Enhances Alveolar Macrophage-Mediated IFN-α/β Response to Respiratory Syncytial Virus

    doi: 10.1128/spectrum.02410-22

    Figure Lengend Snippet: VIP regulates AM and IFN-α/β responses post-RSV infection. (a) AM percentages at 12 h postinfection in lung tissues of KCF mice with or without VIPhyb treatment. (b) IFN-α/β secretion at 12 h postinfection as measured in BALF samples from KCF mice with or without VIPhyb treatment. (c) AM percentages at 12 h postinfection in lung tissues of intact mice with or without VIP treatment. (d) IFN-α/β secretion at 12 h postinfection as measured in BALF samples from intact mice with or without VIP treatment. *, P < 0.05, and **, P < 0.01, compared with RSV or KCF-RSV group; ## , P < 0.01, and ### , P < 0.001, compared with VIP-RSV group. Data are representative of 2 independent experiments. Error bars show SEM.

    Article Snippet: Both VIP and the VIP receptor antagonist VIPhyb were synthesized by GL Biochem Ltd. (Shanghai, China), with purities of >98%.

    Techniques: Infection

    VIP protects against RSV infection. (a) RSV titers in lung tissues of KCF mice with or without VIPhyb treatment. (b) Representative lung histopathological images and scores of KCF mice with or without VIPhyb treatment. Scale bar = 50 μm. (c) RSV titers in lung tissues of intact mice with or without VIP treatment. (d) Representative lung histopathological images and scores of intact mice with or without VIP treatment. *, P < 0.05, and **, P < 0.01, compared with RSV or KCF-RSV group. Data are representative of 2 independent experiments. Error bars show SEM.

    Journal: Microbiology Spectrum

    Article Title: C-Fiber Degeneration Enhances Alveolar Macrophage-Mediated IFN-α/β Response to Respiratory Syncytial Virus

    doi: 10.1128/spectrum.02410-22

    Figure Lengend Snippet: VIP protects against RSV infection. (a) RSV titers in lung tissues of KCF mice with or without VIPhyb treatment. (b) Representative lung histopathological images and scores of KCF mice with or without VIPhyb treatment. Scale bar = 50 μm. (c) RSV titers in lung tissues of intact mice with or without VIP treatment. (d) Representative lung histopathological images and scores of intact mice with or without VIP treatment. *, P < 0.05, and **, P < 0.01, compared with RSV or KCF-RSV group. Data are representative of 2 independent experiments. Error bars show SEM.

    Article Snippet: Both VIP and the VIP receptor antagonist VIPhyb were synthesized by GL Biochem Ltd. (Shanghai, China), with purities of >98%.

    Techniques: Infection

    Sequences of VIPhyb and VIP

    Journal: Microbiology Spectrum

    Article Title: C-Fiber Degeneration Enhances Alveolar Macrophage-Mediated IFN-α/β Response to Respiratory Syncytial Virus

    doi: 10.1128/spectrum.02410-22

    Figure Lengend Snippet: Sequences of VIPhyb and VIP

    Article Snippet: Both VIP and the VIP receptor antagonist VIPhyb were synthesized by GL Biochem Ltd. (Shanghai, China), with purities of >98%.

    Techniques: Sequencing